RT Journal Article
T1 Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
A1 García Quintanilla, Laura
A1 Luaces Rodríguez, Andrea
A1 Gil Martínez, María
A1 Mondelo García, Cristina
A1 Maroñas Amigo, Olalla
A1 Mangas Sanjuán, Víctor
A1 González Barcia, Miguel
A1 Zarra Ferro, Irene
A1 Aguiar Fernández, Pablo
A1 Otero Espinar, Francisco Javier
A1 Fernández Ferreiro, Anxo
K1 Vascular endothelial growth factor/antagonists & inhibitors
K1 Ranibizumab
K1 Aflibercept
K1 Bevacizumab
K1 Age-Related Macular Degeneration
K1 Pharmacokinetics
K1 Intravitreal
AB Intravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodieshas become the standard treatment for Age-Related Macular Degeneration; however, the knowledgeof their pharmacokinetics is limited. A comprehensive review of the preclinical and clinicalpharmacokinetic data that were obtained in different studies with intravitreal bevacizumab,ranibizumab, and aflibercept has been conducted. Moreover, the factors that can influence thevitreous pharmacokinetics of these drugs, as well as the methods that were used in the studiesfor analytical determination, have been exposed. These anti-VEGF drugs present different chargeand molecular weights, which play an important role in vitreous distribution and elimination.The pharmacokinetic parameters that were collected differ depending on the species that wereinvolved in the studies and on physiological and pathological conditions, such as vitrectomy andlensectomy. Knowledge of the intravitreal pharmacokinetics of the anti-VEGF drugs that were usedin clinical practice is of vital importance.
PB MDPI
YR 2019
FD 2019
LK http://hdl.handle.net/10347/21145
UL http://hdl.handle.net/10347/21145
LA eng
NO García-Quintanilla, L.; Luaces-Rodríguez, A.; Gil-Martínez, M.; Mondelo-García, C.; Maroñas, O.; Mangas-Sanjuan, V.; González-Barcia, M.; Zarra-Ferro, I.; Aguiar, P.; Otero-Espinar, F.J.; Fernández-Ferreiro, A. Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration. Pharmaceutics 2019, 11, 365
NO This work was partially supported by the ISCIII (PI17/00940, RETICS Oftared, RD16/0008/0003 and RD12/0034/0017) cofunded by FEDER and by the Spanish Ministry of Science, Innovation and Universities (RTI2018-099597-B-100)
DS Minerva
RD 23 abr 2026